Track Creo Medical Limited — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Creo Medical Limited CREO.L · Stock Open Creo Medical Limited in new tab

13.00 GBX
EPS
-0.06
P/B
149.81
ROE
-38.49
Beta
0.86
Target Price
89.50 GBX
Loading chart...
Key Metrics
Earnings dateSept. 30, 2026
EPS-0.06
Book Value0.13
Price to Book149.81
Debt/Equity29.96
% Insiders20.448%
Growth
Revenue Growth-0.03%
Estimates
Forward P/E-23.93
Forward EPS-0.82
Target Mean Price89.50

DCF Valuation

Tweak assumptions to recompute fair value for Creo Medical Limited (CREO.L)
Currency: GBX
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Creo Medical Limited Logo Creo Medical Limited Analysis (CREO.L)

United Kingdom Health Care Official Website Stock

Is Creo Medical Limited a good investment? Creo Medical Limited (CREO.L) is currently trading at 13.00 GBX. Market analysts have a consensus price target of 89.50 GBX. This suggests a potential upside from current levels.

Earnings Schedule: Creo Medical Limited is expected to release its next earnings report on Sept. 30, 2026. The market consensus estimate for Forward EPS is -0.82.

Investor FAQ

Does Creo Medical Limited pay a dividend?

No, it does not currently pay a dividend.

What asset class is Creo Medical Limited?

Creo Medical Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Sept. 30, 2026. The company currently has a trailing EPS of -0.06.

Company Profile

Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; SlypSeal Flex, an electrosurgical haemostasis device; and SpydrBlade Flex, a bipolar RF and microwave scissor device that grasps, cuts and, coagulates highly perfused tissues. In addition, it provides endotherapy accessories comprising ScopeSnare, an energy-based polypectomy snares; ScopeSnare Cold, a cutting wire for use in endoscopically in the removal of diminutive, sessile and pedunculated polyps, and tissue from within the gastrointestinal (GI) tract; ScopeClip for clip placement in the digestive tract; ScopeInject for endoscopic injection into GI mucosa; ScoprGrasp, a disposable grasping forceps for digestive and bronchial endoscopy; ScopeBite, a portfolio of digestive biopsy forceps; and other products for gastroenterology, pulmonology, and urology. Creo Medical Group PLC was founded in 2003 and is based in Chepstow, the United Kingdom.

Exchange Ticker
LSE (United Kingdom) CREO.L
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion